New analysis of a Phase 3 study of daridorexant shows that 50 mg improved both sleep and daytime functioning compared to placebo in women during menopausal transition ageBrigham and Women’s Hospital to study the effectiveness and safety of daridorexant for menopause-related insomnia symptoms Allschwil, Switzerland – January 5, 2026Idorsia Ltd (SIX: IDIA) announces the publication of “Efficacy and safety of daridorexant for the treatment of insomnia disorder in women during menopausal transition age: Insight ...